Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Agricultureread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
The president also said he "offered to personally vouch" for Rocky's bail. Sweden, however, does not have a bail system.Politicsread more
CoinShares Chief Strategy Officer Meltem Demirors discusses Facebook's Libra project and its impact on the cryptocurrency market after testifying to the House Financial...Fast Moneyread more
Some 40% of Americans would struggle to come up with even $400 to pay for an emergency expense. Just how are so many Americans so short on cash? Blame debt.Personal Financeread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
Pharmaceutical companies may be in the direct path of President Donald Trump's next big policy push to lower drug prices after the administration abandoned a proposal that would have eliminated rebates from government drug plans.
Earlier Thursday, the White House said the Trump administration had withdrawn its plan to ban rebates that drugmakers pay to pharmacy benefit managers. Drug manufacturers pay the rebates to PBMs for getting their drugs covered by Medicare's Part D prescription plan.
Health and Human Services Secretary Alex Azar told reporters Thursday morning that Trump decided to pull the proposal after concerns that it would cause insurance companies to increase premiums for seniors.
"The president is deeply committed to protecting America's seniors," Azar said in a news briefing in Washington, D.C. "We're not going to put seniors at risk of their premiums going up."
Analysts say another way Trump could make a push to lower drug prices is a proposal announced last year that would allow Medicare to create an "international pricing index " to bring drug prices in line with what other nations pay. Pharmaceutical companies oppose the proposal. Merck CEO Ken Frazier has even said he sees a legal challenge if adopted.
Pulling the drug rebate rule "effectively puts other drug price control mechanisms back on the table, which could be worse if implemented and enforced," said Salim Syed, senior biotech analyst at Mizuho Securities.
Ipsita Smolinski, managing director at health-care research and consulting firm Capitol Street, said the pricing index is likely the next policy announcement to come from the administration. "With rebate reform dead, more draconian policies may come with respect to biopharma ... and the markets feel that. Uncertainty is never good," Ipsita said.
Meanwhile, pharma stocks tanked on fears the administration's focus would shift to drugmakers. Pharmaceutical giant Pfizer closed down more than 2%. Shares of Eli Lily and Merck both ended the day down 4%.
The end of the drug rebate proposal is Trump's second setback this week. The news comes three days after a federal judge in Washington, D.C., dealt a blow to the White House by striking down a rule that would have forced pharmaceutical companies to disclose the list price of their drugs in television ads.
The Trump administration is certainly facing difficulties in its drug price push, but it's not a "full-on" roadblock, said Tricia Neuman, director of the Kaiser Family Foundation's Medicare policy program.
"It's a bit too early to write the obituary," Neuman added. "There is bipartisan support for government action in this area. Our polls show Democrats and Republicans are looking to take action."
Trump said last week that he's preparing an executive order declaring a "favored nations clause" for drug prices, where the U.S. will pay no more than the country with the lowest prescription drug prices. On Wednesday, the president signed an executive order designed to reform the nation's kidney treatment industry, which could possibly save the U.S. government millions of dollars.